1,4-naphthoquinones: From oxidative damage to cellular and inter-cellular signaling

Molecules

Volumn 19, Issue 9, 2014, Pages 14902-14918

  Klotz, Lars Oliver ^a,b   Hou, Xiaoqing ^b   Jacob, Claus ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Saarland State University   (Germany)

Author keywords

Connexin; Epidermal growth factor receptor; Gap junction; NQO1; Nrf2; Oxidative stress; Protein tyrosine phosphatases (PTP); Redox cycling

Indexed keywords

1,4-NAPHTHOQUINONE; ALKYLATING AGENT; NAPHTHOQUINONE; PROTEIN TYROSINE KINASE;

ANIMAL; CELL COMMUNICATION; DRUG EFFECTS; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ALKYLATING AGENTS; ANIMALS; CELL COMMUNICATION; HUMANS; NAPHTHOQUINONES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84907434177     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190914902     Document Type: Article

References (73)

1. Ferland, G. The discovery of vitamin K and its clinical applications. Ann. Nutr. Metab. 2012, 61, 213-218.
2. Klaus, V.; Hartmann, T.; Gambini, J.; Graf, P.; Stahl, W.; Hartwig, A.; Klotz, L.O. 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch. Biochem. Biophys. 2010, 496, 93-100.
3. Inbaraj, J.J.; Chignell, C.F. Cytotoxic action of juglone and plumbagin: A mechanistic study using HaCaT keratinocytes. Chem. Res. Toxicol. 2004, 17, 55-62.
4. Kappus, H.; Sies, H. Toxic drug effects associated with oxygen metabolism: Redox cycling and lipid peroxidation. Experientia 1981, 37, 1233-1241.
5. Rooseboom, M.; Commandeur, J.N.; Vermeulen, N.P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
6. Ernster, L. DT Diaphorase: A historical review. Chem. Scr. 1987, 27A, 1-13.
7. Thor, H.; Smith, M.T.; Hartzell, P.; Bellomo, G.; Jewell, S.A.; Orrenius, S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. J. Biol. Chem. 1982, 257, 12419-12425.
8. Nishiyama, T.; Izawa, T.; Usami, M.; Ohnuma, T.; Ogura, K.; Hiratsuka, A. Cooperation of NAD(P)H:quinone oxidoreductase 1 and UDP-glucuronosyltransferases reduces menadione cytotoxicity in HEK293 cells. Biochem. Biophys. Res. Commun. 2010, 394, 459-463.
9. Cadenas, E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol. 1995, 49, 127-140.
10. d'Arcy Doherty, M.; Rodgers, A.; Cohen, G.M. Mechanisms of toxicity of 2- and 5-hydroxy-1, 4-naphthoquinone; absence of a role for redox cycling in the toxicity of 2-hydroxy-1, 4-naphthoquinone to isolated hepatocytes. J. Appl. Toxicol. 1987, 7, 123-129.
11. Abdelmohsen, K.; Gerber, P.A.; von Montfort, C.; Sies, H.; Klotz, L.O. Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43-Role of glutathione and tyrosine phosphatases. J. Biol. Chem. 2003, 278, 38360-38367.
12. Abdelmohsen, K.; Patak, P.; von Montfort, C.; Melchheier, I.; Sies, H.; Klotz, L.O. Signaling effects of menadione: From tyrosine phosphatase inactivation to connexin phosphorylation. Methods Enzymol. 2004, 378, 258-272.
13. Buffinton, G.D.; Öllinger, K.; Brunmark, A.; Cadenas, E. DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autoxidation rates. Biochem. J. 1989, 257, 561-571.
14. Kumagai, Y.; Shinkai, Y.; Miura, T.; Cho, A.K. The chemical biology of naphthoquinones and its environmental implications. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 221-247.
15. Dinkova-Kostova, A.T.; Talalay, P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys . 2010, 501, 116-123.
16. Dinkova-Kostova, A.T.; Fahey, J.W.; Talalay, P. Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). Methods Enzymol. 2004, 382, 423-448.
17. Talalay, P.; de Long, M.J.; Prochaska, H.J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. USA 1988, 85, 8261-8265.
18. Yoshinari, K.; Okino, N.; Sato, T.; Sugatani, J.; Miwa, M. Induction of detoxifying enzymes in rodent white adipose tissue by aryl hydrocarbon receptor agonists and antioxidants. Drug Metab. Dispos. 2006, 34, 1081-1089.
19. Li, Y.; Jaiswal, A.K. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J. Biol. Chem. 1992, 267, 15097-15104.
20. Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1, 45-49.
21. Higgins, L.G.; Kelleher, M.O.; Eggleston, I.M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. Toxicol. Appl. Pharmacol. 2009, 237, 267-280.
22. Higgins, L.G.; Hayes, J.D. The cap'n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. Chem. Biol. Interact. 2011, 192, 37-45.
23. Miura, T.; Shinkai, Y.; Jiang, H.Y.; Iwamoto, N.; Sumi, D.; Taguchi, K.; Yamamoto, M.; Jinno, H.; Tanaka-Kagawa, T.; Cho, A.K.; et al. Initial response and cellular protection through the Keap1/Nrf2 system during the exposure of primary mouse hepatocytes to 1,2-naphthoquinone. Chem. Res. Toxicol. 2011, 24, 559-567.
24. Heiss, E.H.; Schachner, D.; Zimmermann, K.; Dirsch, V.M. Glucose availability is a decisive factor for Nrf2-mediated gene expression. Redox Biol. 2013, 1, 359-365.
25. Eggler, A.L.; Liu, G.; Pezzuto, J.M.; van Breemen, R.B.; Mesecar, A.D. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci. USA 2005, 102, 10070-10075.
26. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; O'Connor, T.; Yamamoto, M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 2003, 8, 379-391.
27. Shay, K.P.; Shenvi, S.; Hagen, T.M. Lipoic acid as an inducer of Phase II detoxification enzymes through activation of Nrf2-dependent gene expression. In Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects; Patel, M.S., Packer, L., Eds.; CRC Press; Taylor & Francis Group: Boca Raton, FL, USA, 2008; pp. 349-371.
28. Ishii, T.; Itoh, K.; Takahashi, S.; Sato, H.; Yanagawa, T.; Katoh, Y.; Bannai, S.; Yamamoto, M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 2000, 275, 16023-16029.
29. Chen, Q.; Cederbaum, A.I. Menadione cytotoxicity to Hep G2 cells and protection by activation of nuclear factor-kappaB. Mol. Pharmacol. 1997, 52, 648-657.
30. Son, T.G.; Camandola, S.; Arumugam, T.V.; Cutler, R.G.; Telljohann, R.S.; Mughal, M.R.; Moore, T.A.; Luo, W.; Yu, Q.S.; Johnson, D.A.; et al. Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J. Neurochem. 2010, 112, 1316-1326.
31. Son, T.G.; Kawamoto, E.M.; Yu, Q.S.; Greig, N.H.; Mattson, M.P.; Camandola, S. Naphthazarin protects against glutamate-induced neuronal death via activation of the Nrf2/ARE pathway. Biochem. Biophys. Res. Commun. 2013, 433, 602-606.
32. Hunt, P.R.; Son, T.G.; Wilson, M.A.; Yu, Q.S.; Wood, W.H.; Zhang, Y.; Becker, K.G.; Greig, N.H.; Mattson, M.P.; Camandola, S.; et al. Extension of lifespan in C. elegans by naphthoquinones that act through stress hormesis mechanisms. PLoS One 2011, 6, e21922.
33. Heidler, T.; Hartwig, K.; Daniel, H.; Wenzel, U. Caenorhabditis elegans lifespan extension caused by treatment with an orally active ROS-generator is dependent on DAF-16 and SIR-2.1. Biogerontology 2010, 11, 183-195.
34. Sun, Z.; Huang, Z.; Zhang, D.D. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 2009, 4, e6588.
35. Klotz, L.O.; Patak, P.; Ale-Agha, N.; Buchczyk, D.P.; Abdelmohsen, K.; Gerber, P.A.; von Montfort, C.; Sies, H. 2-Methyl-1,4-naphthoquinone, vitamin K(3), decreases gap-junctional intercellular communication via activation of the epidermal growth factor receptor/extracellular signal-regulated kinase cascade. Cancer Res. 2002, 62, 4922-4928.
36. Beier, J.I.; von Montfort, C.; Sies, H.; Klotz, L.O. Activation of ErbB2 by 2-methyl-1, 4-naphthoquinone (menadione) in human keratinocytes: Role of EGFR and protein tyrosine phosphatases. FEBS Lett. 2006, 580, 1859-1864.
37. Öllinger, K.; Brunmark, A. Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J. Biol. Chem. 1991, 266, 21496-21503.
38. O'Brien, P.J. Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interact. 1991, 80, 1-41.
39. Kim, Y.; Lee, J.J.; Lee, S.G.; Jung, S.H.; Han, J.H.; Yang, S.Y.; Yun, E.; Song, G.Y.; Myung, C.S. 5,8-Dimethoxy-2-Nonylamino-Naphthalene-1,4-Dione Inhibits Vascular Smooth Muscle Cell Proliferation by Blocking Autophosphorylation of PDGF-Receptor beta. Korean J. Physiol. Pharmacol. 2013, 17, 203-208.
40. Lee, J.J.; Zhang, W.Y.; Yi, H.; Kim, Y.; Kim, I.S.; Shen, G.N.; Song, G.Y.; Myung, C.S. Anti-proliferative actions of 2-decylamino-5,8-dimethoxy-1,4-naphthoquinone in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2011, 411, 213-218.
41. Kim, Y.; Han, J.H.; Yun, E.; Jung, S.H.; Lee, J.J.; Song, G.Y.; Myung, C.S. Inhibitory effect of a novel naphthoquinone derivative on proliferation of vascular smooth muscle cells through suppression of platelet-derived growth factor receptor beta tyrosine kinase. Eur. J. Pharmacol. 2014, 733, 81-89.
42. Abdelmohsen, K.; Sauerbier, E.; Ale-Agha, N.; Beier, J.I.; Walter, P.; Galban, S.; Stuhlmann, D.; Sies, H.; Klotz, L.O. Epidermal growth factor- and stress-induced loss of gap junctional communication is mediated by ERK-1/ERK-2 but not ERK-5 in rat liver epithelial cells. Biochem. Biophys. Res. Commun. 2007, 364, 313-317.
43. Melchheier, I.; von Montfort, C.; Stuhlmann, D.; Sies, H.; Klotz, L.O. Quinone-induced Cdc25A inhibition causes ERK-dependent connexin phosphorylation. Biochem. Biophys. Res. Commun. 2005, 327, 1016-1023.
44. Lazo, J.S.; Nemoto, K.; Pestell, K.E.; Cooley, K.; Southwick, E.C.; Mitchell, D.A.; Furey, W.; Gussio, R.; Zaharevitz, D.W.; Joo, B.; et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. 2002, 61, 720-728.
45. Nemoto, K.; Vogt, A.; Oguri, T.; Lazo, J.S. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells. Prostate 2004, 58, 95-102.
46. Kyriakis, J.M.; Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol. Rev. 2012, 92, 689-737.
47. Laird, D.W. Life cycle of connexins in health and disease. Biochem. J. 2006, 394, 527-543.
48. Valiunas, V.; Polosina, Y.Y.; Miller, H.; Potapova, I.A.; Valiuniene, L.; Doronin, S.; Mathias, R.T.; Robinson, R.B.; Rosen, M.R.; Cohen, I.S.; et al. Connexin-specific cell-to-cell transfer of short interfering RNA by gap junctions. J. Physiol. 2005, 568, 459-468.
49. Lampe, P.D.; Lau, A.F. The effects of connexin phosphorylation on gap junctional communication. Int. J. Biochem. Cell. Biol. 2004, 36, 1171-1186.
50. Warn-Cramer, B.J.; Lau, A.F. Regulation of gap junctions by tyrosine protein kinases. Biochim. Biophys. Acta 2004, 1662, 81-95.
51. Warn-Cramer, B.J.; Lampe, P.D.; Kurata, W.E.; Kanemitsu, M.Y.; Loo, L.W.; Eckhart, W.; Lau, A.F. Characterization of the mitogen-activated protein kinase phosphorylation sites on the connexin-43 gap junction protein. J. Biol. Chem. 1996, 271, 3779-3786.
52. Warn-Cramer, B.J.; Cottrell, G.T.; Burt, J.M.; Lau, A.F. Regulation of connexin-43 gap junctional intercellular communication by mitogen-activated protein kinase. J. Biol. Chem. 1998, 273, 9188-9196.
53. Abdelmohsen, K.; von Montfort, C.; Stuhlmann, D.; Gerber, P.A.; Decking, U.K.; Sies, H.; Klotz, L.O. Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells. Biol. Chem. 2005, 386, 217-223.
54. McMillan, D.C.; Sarvate, S.D.; Oatis, J.E., Jr.; Jollow, D.J. Role of oxidant stress in lawsone-induced hemolytic anemia. Toxicol. Sci. 2004, 82, 647-655.
55. Ale-Agha, N.; Albrecht, C.; Klotz, L.O. Loss of gap junctional intercellular communication in rat lung epithelial cells exposed to quartz particles. Biochem. Biophys. Res. Commun. 2009, 390, 44-47.
56. Ale-Agha, N.; Albrecht, C.; Klotz, L.O. Loss of gap junctional intercellular communication in rat lung epithelial cells exposed to carbon or silica-based nanoparticles. Biol. Chem. 2010, 391, 1333-1339.
57. Klotz, L.O. Posttranscriptional regulation of connexin-43 expression. Arch. Biochem. Biophys. 2012, 524, 23-29.
58. Ale-Agha, N.; Galban, S.; Sobieroy, C.; Abdelmohsen, K.; Gorospe, M.; Sies, H.; Klotz, L.O. HuR regulates gap junctional intercellular communication by controlling beta-catenin levels and adherens junction integrity. Hepatology 2009, 50, 1567-1576.
59. Östman, A.; Frijhoff, J.; Sandin, A.; Böhmer, F.D. Regulation of protein tyrosine phosphatases by reversible oxidation. J. Biochem. 2011, 150, 345-356.
60. Iwamoto, N.; Sumi, D.; Ishii, T.; Uchida, K.; Cho, A.K.; Froines, J.R.; Kumagai, Y. Chemical knockdown of protein-tyrosine phosphatase 1B by 1,2-naphthoquinone through covalent modification causes persistent transactivation of epidermal growth factor receptor. J. Biol. Chem. 2007, 282, 33396-33404.
61. Padhye, S.; Dandawate, P.; Yusufi, M.; Ahmad, A.; Sarkar, F.H. Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev. 2012, 32, 1131-1158.
62. Aykin-Burns, N.; Ahmad, I.M.; Zhu, Y.; Oberley, L.W.; Spitz, D.R. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J. 2009, 418, 29-37.
63. Sun, W.; Kalen, A.L.; Smith, B.J.; Cullen, J.J.; Oberley, L.W. Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res. 2009, 69, 4294-4300.
64. Sun, W.G.; Weydert, C.J.; Zhang, Y.; Yu, L.; Liu, J.; Spitz, D.R.; Cullen, J.J.; Oberley, L.W. Superoxide Enhances the Antitumor Combination of AdMnSOD Plus BCNU in Breast Cancer. Cancers (Basel) 2010, 2, 68-87.
65. Fry, F.H.; Holme, A.L.; Giles, N.M.; Giles, G.I.; Collins, C.; Holt, K.; Pariagh, S.; Gelbrich, T.; Hursthouse, M.B.; Gutowski, N.J.; et al. Multifunctional redox catalysts as selective enhancers of oxidative stress. Org. Biomol. Chem. 2005, 3, 2579-2587.
66. Döpp, F. Aktivierung der extrazellulär regulierten Kinasen (ERK) 1 und 2 durch selen- und tellurhaltige Naphthochinonderivate in Rattenleberepithelzellen. MD Thesis; Heinrich-Heine- Universität Düsseldorf: Düsseldorf, Germany, December 2007.
67. Donzelli, M.; Draetta, G.F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 2003, 4, 671-677.
68. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
69. Yarden, Y.; Pines, G. The ERBB network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12, 553-563.
70. Tebbutt, N.; Pedersen, M.W.; Johns, T.G. Targeting the ERBB family in cancer: Couples therapy. Nat. Rev. Cancer 2013, 13, 663-673.
71. Gerber, P.A.; Buhren, B.A.; Kürle, S.; Homey, B. Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors. Spektrum kutaner Nebenwirkungen. Hautarzt 2010, 61, 654-661.
72. Potthoff, K.; Hofheinz, R.; Hassel, J.C.; Volkenandt, M.; Lordick, F.; Hartmann, J.T.; Karthaus, M.; Riess, H.; Lipp, H.P.; Hauschild, A.; et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann. Oncol. 2011, 22, 524-535.
73. Perez-Soler, R.; Zou, Y.; Li, T.; Tornos, C.; Ling, Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J. Clin. Oncol. 2006, 24, 3036.